- Home
- ASMB vs RGLS Comparison
ASMB vs RGLS Comparison
Compare ASMB & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- RGLS
- Stock Information
- Founded
- ASMB 2005
- RGLS 2007
- Country
- ASMB United States
- RGLS United States
- Employees
- ASMB N/A
- RGLS N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- RGLS Health Care
- Exchange
- ASMB Nasdaq
- RGLS Nasdaq
- Market Cap
- ASMB 92.1M
- RGLS 102.1M
- IPO Year
- ASMB 2010
- RGLS 2012
- Fundamental
- Price
- ASMB $14.82
- RGLS $1.25
- Analyst Decision
- ASMB Buy
- RGLS Strong Buy
- Analyst Count
- ASMB 2
- RGLS 6
- Target Price
- ASMB $35.00
- RGLS $10.33
- AVG Volume (30 Days)
- ASMB 32.6K
- RGLS 304.6K
- Earning Date
- ASMB 11-07-2024
- RGLS 03-20-2025
- Dividend Yield
- ASMB N/A
- RGLS N/A
- EPS Growth
- ASMB N/A
- RGLS N/A
- EPS
- ASMB N/A
- RGLS N/A
- Revenue
- ASMB $28,326,000.00
- RGLS N/A
- Revenue This Year
- ASMB $282.16
- RGLS N/A
- Revenue Next Year
- ASMB N/A
- RGLS N/A
- P/E Ratio
- ASMB N/A
- RGLS N/A
- Revenue Growth
- ASMB N/A
- RGLS N/A
- 52 Week Low
- ASMB $9.84
- RGLS $1.16
- 52 Week High
- ASMB $19.93
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- ASMB 42.21
- RGLS 34.82
- Support Level
- ASMB $14.15
- RGLS $1.24
- Resistance Level
- ASMB $14.95
- RGLS $1.33
- Average True Range (ATR)
- ASMB 0.87
- RGLS 0.10
- MACD
- ASMB -0.12
- RGLS -0.02
- Stochastic Oscillator
- ASMB 8.97
- RGLS 12.77
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.